

## A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

#### Inclusion Criteria:

- newly diagnosed or relapse of granulomatosis and induction treatment with cyclophosphamide or rituximab is needed - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete Inclusion criteria

---

#### Exclusion Criteria:

- any other known multisystem autoimmune disease - had a kidney transplant - cancer in the past 5 years - any significant cardiovascular disease - taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone equivalent for more than 6 weeks - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete Exclusion criteria

### Conditions & Interventions

#### Conditions:

Immune Diseases

#### Keywords:

Clinics and Surgery Center (CSC), Antineutrophil Cytoplasmic Antibody-associated Vasculitis, Vasculitis

### More Information

**Description:** To evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)

**Study Contact:** Madeline Moore - [moor1449@umn.edu](mailto:moor1449@umn.edu)

**Principal Investigator:** Sahar Koubar

**Phase:** PHASE4

**IRB Number:** STUDY00020711

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.